Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients

被引:23
作者
Goldwasser, F
Buthaud, X
Gross, M
Bleuzen, P
Cvitkovic, E
Voinea, A
Jasmin, C
Romain, D
Misset, JL
机构
[1] Hop Paul Brousse, FSMSIT, Expt Therapeut & Translat Res Sect, F-94800 Villejuif, France
[2] SmithKline Beecham Labs Pharmaceut, F-92731 Nanterre, France
关键词
ovarian cancer; platelet; topotecan; toxicity;
D O I
10.1097/00001813-199903000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in patients receiving topotecan to optimize the clinical management of topotecan hematotoxicity, Twenty-one advanced ovarian cancer patients, all pretreated with cisplatin and paclitaxel, were treated with 1.25 mg/m(2)/day topotecan as a 30 min infusion for 5 days, every 3 weeks, No prophylactic granulocyte colony stimulating factor (G-CSF) was given, No topotecan dose reduction was planned according to hematologic toxicity. One hundred and thirty-three topotecan courses were administered (median per patient 6; range: 1-15). Despite no dose reduction, the mean platelet nadir values were significantly less pronounced at cycle 2 than at cycle 1 (82 versus 46 x 10(3)/mm(3), p=0.0007), Similar differences were found between cycle 1 and any following cycle, The percent of patients experiencing grade 4 thrombocytopenia decreased from 43% at the first cycle, to 15 and 19% at the second and third courses, respectively (p=0.058). We conclude that the currently recommended topotecan schedule is feasible in heavily pretreated ovarian cancer patients without prophylactic G-CSF, The severity of topotecan-induced thrombocytopenia is maximal at the first cycle but significantly decreases from the second cycle in the absence of dose reduction, [(C) 1999 Lippincott Williams & Wilkins.]
引用
收藏
页码:263 / 265
页数:3
相关论文
共 7 条
  • [1] Cass I, 1998, GYNECOL ONCOL, V69, P175, DOI 10.1006/gyno.1998.4966
  • [2] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [3] GROCHOW LB, 1992, DRUG METAB DISPOS, V20, P706
  • [4] Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan
    O'Reilly, S
    Armstrong, DK
    Grochow, LB
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 67 (03) : 329 - 330
  • [5] Phase I and pharmacologic study of topotecan in patients with impaired renal function
    OReilly, S
    Rowinsky, EK
    Slichenmyer, W
    Donehower, RC
    Forastiere, AA
    Ettinger, DS
    Chen, TL
    Sartorius, S
    Grochow, LB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) : 3062 - 3073
  • [6] ROWINSKY EK, 1997, SEMIN ONCOL, V24
  • [7] THE CURRENT STATUS OF CAMPTOTHECIN ANALOGS AS ANTITUMOR AGENTS
    SLICHENMYER, WJ
    ROWINSKY, EK
    DONEHOWER, RC
    KAUFMANN, SH
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (04): : 271 - 291